stockrow
Friday 6 November 2026
Export ARQT’s income statement to Excel — free account
Arcutis Biotherapeutics, Inc.
ARQT Healthcare Biotechnology
Arcutis Biotherapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $376.1 million, up 91.3% from fiscal 2024.
- Revenue
- +45.1%
- EPS
- +12.0%
- Free cash flow
- +1,171.9%
- Total debt
- +0.83%
Quarter to September 2026, against a year earlier
25.55
1.45
−5.37%
Follow ARQT
Alert me
| Sep '26 | Jun '26 | Mar '26 | Dec '25 | Older periods | |
|---|---|---|---|---|---|
Piotroski F-Score |
7 | 7 | 6 | 4 |
+8 more TTM periods Free account |
| 14.88% | 15.86% | (1.43%) | (9.30%) | ||
| 6.68% | 6.78% | (0.59%) | (4.13%) | ||
ROIC |
23.48% | 23.62% | 2.69% | (9.91%) | |
Return on Tangible Assets |
9.01% | 9.25% | (0.86%) | (5.71%) | |
Average Days of Receivables |
122.90 | 122.06 | 126.79 | 141.92 | |
Free Cash Flow per Share |
0.46 | 0.30 | 0.21 | (0.17) | |
Free Cash Flow |
59.71 | 39.07 | 26.99 | (21.31) | |
Capital Expenditures |
(0.25) | (0.24) | — | (15.69) | |
| Other line items | |||||
Cash ROIC |
9.74% | 6.87% | 5.16% | (4.10%) | |
Accounts Receivable Turnover |
3.55 | 3.54 | 3.62 | 3.43 | |
Accounts Payable Turnover |
6.35 | 3.79 | 1.76 | 2.74 | |
Inventory Turnover |
1.32 | 1.49 | 1.39 | 1.98 | |
Average Days of Payables |
67.86 | 58.65 | 177.38 | 124.61 | |
Days of Inventory on Hand |
371.49 | 345.31 | 362.50 | 225.14 | |
Tax Rate |
(0.03) | (0.03) | 0.71 | 0.08 | |
Research and Development Expense of Revenue |
18.45% | 19.62% | 21.69% | 20.49% | |
Selling, General and Administrative Expense of Revenue |
65.82% | 64.14% | 68.48% | 73.01% | |
Share Based Compensation of Revenue |
9.02% | 9.39% | 9.93% | 10.73% | |
Interest Coverage |
2.56 | 2.47 | 0.24 | (1.01) | |
Operating CF/Net income |
2.00 | 1.38 | (11.36) | 0.35 | |
Depreciation/Fixed assets |
2.12 | 1.50 | 0.80 | 2.47 | |
Capex/Depreciation |
(0.15) | (0.18) | 0.00 | (6.10) | |
Revenue per Share |
3.88 | 3.55 | 3.21 | 2.96 | |
Operating CF per Share |
0.46 | 0.30 | 0.21 | (0.04) | |
Capex per Share |
0.00 | 0.00 | 0.00 | (0.12) | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.04 |
Columns are period end dates · fundamentals updated 6 Nov 2026